Kusumesh R, Ambasta A, Arya LK, et al. - Researchers sought to inscribe the characteristic clinical features and management of keratitis in the patients receiving miltefosine for post-kala-azar dermal leishmaniasis (PKDL) via retrospectively reviewing the medical records of five patients with PKDL who presented with keratitis from April 2018 to December 2019. Following ocular symptoms were reported: pain, redness, watering, photophobia and diminution of vision. All patients showed peripheral, paralimbal, ring-shaped, full-thickness stromal infiltration resulting in ulcerative keratitis in Slit-lamp biomicroscopy. Receipt of miltefosine for an average period of 48 days was reported in all five patients before the onset of keratitis. Based on these observations, it can be concluded that keratitis resembling infectious keratitis might occur in correlation with receiving miltefosine for prolonged duration. For successful management of the cases, they emphasize early diagnosis with discontinuation of the drug and initiation of corticosteroid therapy as significant.